Regulation of metastasis by microRNAs in ovarian cancer

Yongchao Wang, Sangmi Kim, Il-man Kim

Research output: Contribution to journalShort survey

38 Citations (Scopus)

Abstract

Ovarian cancer (OC) is the second most common and the most fatal gynecologic cancer in the United States. Over the last decade, various targeted therapeutics have been introduced but there has been no corresponding improvement in patient survival mainly because of the lack of effective early detection methods. microRNAs (miRs) are small, non-coding RNAs that regulate gene expression post-transcriptionally. Accumulating data suggest central regulatory roles of miRs in modulating OC initiation, progression, and metastasis. More recently, aberrant miR expression has been also associated with cancer stem cell (CSC) phenotypes and development of CSC chemo-resistance. Here, we review recent advances on miRs and OC metastasis and discuss the concept that miRs are involved in both CSC transformation and subsequent OC metastasis. Finally, we describe the prevalence of circulating miRs and assess their potential utilities as biomarkers for OC diagnosis, prognosis, and therapeutics.

Original languageEnglish (US)
Article number143
JournalFrontiers in Oncology
Volume4 JUN
DOIs
StatePublished - Jan 1 2014

Fingerprint

MicroRNAs
Ovarian Neoplasms
Neoplastic Stem Cells
Neoplasm Metastasis
Small Untranslated RNA
Biomarkers
Phenotype
Gene Expression
Survival
Therapeutics
Neoplasms

Keywords

  • Angiogenesis
  • Cancer stem cells
  • Epithelial-mesenchymal transition
  • Extracellular matrix
  • Ovarian cancer
  • miRs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Regulation of metastasis by microRNAs in ovarian cancer. / Wang, Yongchao; Kim, Sangmi; Kim, Il-man.

In: Frontiers in Oncology, Vol. 4 JUN, 143, 01.01.2014.

Research output: Contribution to journalShort survey

Wang, Yongchao ; Kim, Sangmi ; Kim, Il-man. / Regulation of metastasis by microRNAs in ovarian cancer. In: Frontiers in Oncology. 2014 ; Vol. 4 JUN.
@article{fa35b4829ded43f5935011570847637d,
title = "Regulation of metastasis by microRNAs in ovarian cancer",
abstract = "Ovarian cancer (OC) is the second most common and the most fatal gynecologic cancer in the United States. Over the last decade, various targeted therapeutics have been introduced but there has been no corresponding improvement in patient survival mainly because of the lack of effective early detection methods. microRNAs (miRs) are small, non-coding RNAs that regulate gene expression post-transcriptionally. Accumulating data suggest central regulatory roles of miRs in modulating OC initiation, progression, and metastasis. More recently, aberrant miR expression has been also associated with cancer stem cell (CSC) phenotypes and development of CSC chemo-resistance. Here, we review recent advances on miRs and OC metastasis and discuss the concept that miRs are involved in both CSC transformation and subsequent OC metastasis. Finally, we describe the prevalence of circulating miRs and assess their potential utilities as biomarkers for OC diagnosis, prognosis, and therapeutics.",
keywords = "Angiogenesis, Cancer stem cells, Epithelial-mesenchymal transition, Extracellular matrix, Ovarian cancer, miRs",
author = "Yongchao Wang and Sangmi Kim and Il-man Kim",
year = "2014",
month = "1",
day = "1",
doi = "10.3389/fonc.2014.00143",
language = "English (US)",
volume = "4 JUN",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Regulation of metastasis by microRNAs in ovarian cancer

AU - Wang, Yongchao

AU - Kim, Sangmi

AU - Kim, Il-man

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Ovarian cancer (OC) is the second most common and the most fatal gynecologic cancer in the United States. Over the last decade, various targeted therapeutics have been introduced but there has been no corresponding improvement in patient survival mainly because of the lack of effective early detection methods. microRNAs (miRs) are small, non-coding RNAs that regulate gene expression post-transcriptionally. Accumulating data suggest central regulatory roles of miRs in modulating OC initiation, progression, and metastasis. More recently, aberrant miR expression has been also associated with cancer stem cell (CSC) phenotypes and development of CSC chemo-resistance. Here, we review recent advances on miRs and OC metastasis and discuss the concept that miRs are involved in both CSC transformation and subsequent OC metastasis. Finally, we describe the prevalence of circulating miRs and assess their potential utilities as biomarkers for OC diagnosis, prognosis, and therapeutics.

AB - Ovarian cancer (OC) is the second most common and the most fatal gynecologic cancer in the United States. Over the last decade, various targeted therapeutics have been introduced but there has been no corresponding improvement in patient survival mainly because of the lack of effective early detection methods. microRNAs (miRs) are small, non-coding RNAs that regulate gene expression post-transcriptionally. Accumulating data suggest central regulatory roles of miRs in modulating OC initiation, progression, and metastasis. More recently, aberrant miR expression has been also associated with cancer stem cell (CSC) phenotypes and development of CSC chemo-resistance. Here, we review recent advances on miRs and OC metastasis and discuss the concept that miRs are involved in both CSC transformation and subsequent OC metastasis. Finally, we describe the prevalence of circulating miRs and assess their potential utilities as biomarkers for OC diagnosis, prognosis, and therapeutics.

KW - Angiogenesis

KW - Cancer stem cells

KW - Epithelial-mesenchymal transition

KW - Extracellular matrix

KW - Ovarian cancer

KW - miRs

UR - http://www.scopus.com/inward/record.url?scp=84904612549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904612549&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00143

DO - 10.3389/fonc.2014.00143

M3 - Short survey

AN - SCOPUS:84904612549

VL - 4 JUN

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 143

ER -